Ironwood Pharma Spins off Cyclerion Therapeutics With 5 Orphan Disease Compounds

Ironwood Pharma Spins off Cyclerion Therapeutics With 5 Orphan Disease Compounds

Source: 
BioSpace
snippet: 

In late-February, Cambridge, Mass.-based Ironwood Pharmaceuticals announced it had entered into a private placement deal of up to $175 million that would be used to support its spinoff of Cyclerion Therapeutics. Today, Cyclerion has been launched on the second floor of a 200,000-square-foot, 3-story space on Binney Street, in Cambridge.